Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression
about
Do Xpert MTB/RIF Cycle Threshold Values Provide Information about Patient Delays for Tuberculosis Diagnosis?Utility of Second-Generation Line Probe Assay (Hain MTBDRplus) Directly on 2-Month Sputum Specimens for Monitoring Tuberculosis Treatment Response.Update in Mycobacterium tuberculosis lung disease 2014.Improving the sensitivity of the Xpert MTB/RIF assay on sputum pellets by decreasing the amount of added sample reagent: a laboratory and clinical evaluation.The utility of Xpert MTB/RIF performed on bronchial washings obtained in patients with suspected pulmonary tuberculosis in a high prevalence setting.The use of digital PCR to improve the application of quantitative molecular diagnostic methods for tuberculosisThe diagnostic accuracy of the MTBDRplus and MTBDRsl assays for drug-resistant TB detection when performed on sputum and culture isolates.The role of Xpert MTB/RIF in diagnosing pulmonary tuberculosis in post-mortem tissues.Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?False-positive rifampin resistant results with Xpert MTB/RIF version 4 assay in clinical samples with a low bacterial load.Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments.Update in Viral Infections 2014.Microencapsulation of Lefty-secreting engineered cells for pulmonary fibrosis therapy in mice.[Role of GeneXpert MTB/RIF test in the screening for pulmonary tuberculosis at the General Referral Provincial Hospital of Bukavu, in the East of the Democratic Republic of the Congo: balance after 10 months of use].Correlation of Xpert MTB/RIF with measures to assess Mycobacterium tuberculosis bacillary burden in high HIV burden areas of Southern Africa.Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial
P2860
Q28389038-7635F1DF-0B45-4066-B44F-E42DE5B446E9Q33603890-167AE20F-6513-40A3-98B9-168FF76040E9Q33735642-9C041290-66E0-4AD0-86FD-1E89C1F530EEQ35193361-2BA23E9F-1A75-4672-9159-37D22BDF3A85Q35777843-21408716-EC2A-4770-92D1-78A0EFA5E092Q36094092-860D38BF-5DD6-4CD9-AAF7-4278717CBF02Q36564933-66236F58-F5E7-4B2B-A58D-BAE9433B5393Q36565048-95DBC0A5-0D6F-4E0D-A97C-BA22BF4847F9Q36715814-229C0890-4ABB-44EB-A540-2043E322ACB1Q36827305-56658682-3AA9-4839-810C-27943C617D5CQ37732922-B3257A48-EBC9-4328-8DC9-4B757E91FB9BQ38587113-3EFA5C68-28A9-4215-9055-501A13EB6B44Q40329746-826D9352-32C8-4232-BA7C-37433838B130Q45784038-34611828-3925-48A8-B0E0-8B62F5F071D8Q54957532-234C3EF5-31FE-4394-9694-AAF1E84868BEQ57276328-C63ABEDD-BF07-428C-BC0A-E075D21B5A6F
P2860
Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Xpert MTB/RIF as a measure of ...... V status and immunosuppression
@ast
Xpert MTB/RIF as a measure of ...... V status and immunosuppression
@en
type
label
Xpert MTB/RIF as a measure of ...... V status and immunosuppression
@ast
Xpert MTB/RIF as a measure of ...... V status and immunosuppression
@en
prefLabel
Xpert MTB/RIF as a measure of ...... V status and immunosuppression
@ast
Xpert MTB/RIF as a measure of ...... V status and immunosuppression
@en
P2093
P2860
P50
P1476
Xpert MTB/RIF as a measure of ...... V status and immunosuppression
@en
P2093
Grant Theron
Jean Bassett
Lesley Scott
Wendy Stevens
P2860
P304
P356
10.1164/RCCM.201312-2140OC
P407
P577
2014-06-01T00:00:00Z